Checkpoint Inhibitor Refractory Cancer

Checkpoint Inhibitor Refractory Cancer

Checkpoint inhibitors are a type of immunotherapy that works by blocking certain proteins in cancer cells, allowing the immune system to recognize and attack cancer more effectively. Cancer is a major cause of morbidity and mortality worldwide. As the global population ages, the incidence of cancer is expected to increase, creating a growing demand for cancer treatments including checkpoint inhibitor refractory cancer market. According to the World Health Organization, Cancer is one of the leading causes of death worldwide, killing nearly 10 million people in 2020, or nearly one in six.

Checkpoint Inhibitor Refractory Cancer Market is expected to grow at a strong CAGR of 12% during the forecast period owing to the significant advancements in cancer research. For instance, The Chinese People's Liberation Army General Hospital is conducting a phase I trial of GSL synthetase inhibitors alone or in combination with immune checkpoint inhibitors in the treatment of patients with advanced relapsed or refractory hematologic malignancies and previously treated solid tumors.

• Based on type, the market is segmented into PD-1 inhibitor, PD-L1 inhibitor, and others. As per our analysis, the PD-1 inhibitor segment held a significant share in 2022. The growing use of combination therapies, involving the use of multiple cancer treatments in combination to improve treatment outcomes is the important reason for the considerable share of the segment. PD-1 inhibitors are often used in combination with other immunotherapies, such as CTLA-4 inhibitors and immune checkpoint agonists, to enhance their effectiveness.
• Based on the application, the market is segmented into lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. The Hodgkin lymphoma segment is expected to grow with a higher CAGR in the checkpoint inhibitor refractory cancer market during the forecast period. The increasing incidences of Hodgkin lymphoma are the major driving factor for the fast growth of the anesthesia segment. For instance, according to Cancer.Net, in 2020, 3,087 people were diagnosed with Hodgkin lymphoma in 2020 globally.
• For a better understanding of the market adoption of the industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North America held dominating share in the checkpoint inhibitor refractory cancer market in 2022. North America has a high incidence of cancer, which has led to a greater demand for cancer treatments, including checkpoint inhibitors. For instance, as per the Canada Cancer Registry, in 2020, about 140,330 new cancer cases were diagnosed in Canada. Further, North America is known for being an early adopter of new cancer treatments, which has led to a greater demand for checkpoint inhibitors in the region
• Some of the major players operating in the market include Bristol-Myers Squibb Company; AstraZeneca; Merck KGaA; F. Hoffmann-La Roche Ltd; Regeneron Pharmaceuticals Inc; Pfizer Inc; Janssen Global Services, LLC; 4SC AG; Mirati Therapeutics, Inc.; and Ascentage Pharma.